[HTML][HTML] Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment
AE Onuma, H Zhang, H Huang, TM Williams… - Gene …, 2020 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy worldwide
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …
[HTML][HTML] Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in patients with hepatocellular carcinoma
Simple Summary Immune checkpoint inhibitors (ICIs) are now a cornerstone of systemic
treatment for hepatocellular carcinoma (HCC). However, their efficacy is blunted by …
treatment for hepatocellular carcinoma (HCC). However, their efficacy is blunted by …
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
U Harkus, M Wankell, P Palamuthusingam… - Seminars in Cancer …, 2022 - Elsevier
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths in the
world, and for patients with advanced disease there are few therapeutic options available …
world, and for patients with advanced disease there are few therapeutic options available …
Immune checkpoint inhibitor resistance in hepatocellular carcinoma
Z Wang, Y Wang, P Gao, J Ding - Cancer letters, 2023 - Elsevier
The application of immune checkpoint inhibitors (ICIs) has markedly enhanced the treatment
of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown …
of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown …
Adverse effects of immune-checkpoint inhibitors in hepatocellular carcinoma
T Cui, Y Liu, J Wang, L Liu - OncoTargets and therapy, 2020 - Taylor & Francis
Immune-modulatory therapy, especially with immune-checkpoint inhibitors (ICIs), has
reshaped cancer therapeutics. Immunotherapy is relatively a novel approach that can …
reshaped cancer therapeutics. Immunotherapy is relatively a novel approach that can …
[HTML][HTML] Lessons from immune checkpoint inhibitor trials in hepatocellular carcinoma
R Mohr, F Jost-Brinkmann, B Özdirik… - Frontiers in …, 2021 - frontiersin.org
The implementation of immune checkpoint inhibitors (ICI) into the clinical management of
different malignancies has largely changed our understanding of cancer treatment. After …
different malignancies has largely changed our understanding of cancer treatment. After …
[HTML][HTML] Immune checkpoint inhibitors in hepatocellular carcinoma: current progresses and challenges
HT Liu, MJ Jiang, ZJ Deng, L Li, JL Huang… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world
and its incidence is increasing in many countries. In recent years, with the deepening …
and its incidence is increasing in many countries. In recent years, with the deepening …
[HTML][HTML] Current landscape of immune checkpoint inhibitor therapy for hepatocellular carcinoma
Simple Summary Hepatocellular carcinoma (HCC) is the most common primary hepatic
malignancy, with increasing incidence over the past several decades. The majority of …
malignancy, with increasing incidence over the past several decades. The majority of …
Immune checkpoint inhibitors for hepatocellular carcinoma
I El Dika, DN Khalil, GK Abou‐Alfa - Cancer, 2019 - Wiley Online Library
The position of immunotherapy as a pillar of systemic cancer treatment has been firmly
established over the past decade. Immune checkpoint inhibitors are a welcome option for …
established over the past decade. Immune checkpoint inhibitors are a welcome option for …
[HTML][HTML] Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma
A Rizzo, G Brandi - Cancer treatment and research communications, 2021 - Elsevier
Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …
相关搜索
- checkpoint inhibitors hepatocellular carcinoma
- checkpoint inhibitors biomarkers of response
- checkpoint inhibitors mechanisms of resistance
- hepatocellular cancer biomarkers of response
- hepatocellular cancer mechanisms of resistance
- checkpoint inhibitors diagnosis and management
- checkpoint inhibitors biochemical predictors
- checkpoint inhibitors hepatocellular cancer
- checkpoint inhibitors management of toxicities